{"product_id":"the-brigham-and-dana-farber","title":"The Brigham and Dana-Farber Board Review in Hematology and Oncology 2018","description":"\u003ch3\u003eThe Brigham and Dana-Farber Board Review in Hematology and Oncology 2018\u003c\/h3\u003e\n\u003cdiv\u003eThe Brigham and Dana-Farber Board Review in Hematology and Oncology\u003c\/div\u003e\n\u003cdiv\u003eBrigham and Women’s Hospital Board Review\u003c\/div\u003e\n\u003cdiv\u003e\u003c\/div\u003e\n\u003cdiv\u003eThis comprehensive CME program offers an in-depth, case-base review of the clinical essentials in hematology and oncology. Ideal for MOC.\u003c\/div\u003e\n\u003ch3\u003eImprove Patient Care in Hematology and Oncology\u003c\/h3\u003e\n\u003cdiv\u003eThe Brigham and Dana-Farber Board Review in Hematology and Oncology will help improve clinical practice gaps in hematology and oncology derived from the American Board of Internal Medicine (ABIM) certification\/recertification requirements. Relevant topics are addressed in case-based board review presentations. Improve patient care by learning to:\u003c\/div\u003e\n\u003cul\u003e\n\u003cli\u003ePerform differential diagnosis of complex hematologic and oncologic disorders\u003c\/li\u003e\n\u003cli\u003eIdentify and apply current therapeutic options for hematologic and oncologic disorders\u003c\/li\u003e\n\u003cli\u003eEvaluate and interpret up-to-date literature relevant to hematology and oncology\u003c\/li\u003e\n\u003cli\u003eIllustrate knowledge of pathophysiology of hematologic and oncologic disorders\u003c\/li\u003e\n\u003cli\u003eIllustrate knowledge of pathophysiology as it applies to management of Hematology and Oncology disorders\u003c\/li\u003e\n\u003cli\u003eApply knowledge gained to the ABIM certification\/recertification Hematology and Oncology examinations\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eTOPICS\/SPEAKERS\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003eMolecular Genetics of Cancer – Nikhil Wagle, MD\u003c\/li\u003e\n\u003cli\u003eAdvances in Cancer Drug Development – Geoffrey I. Shapiro, MD, PhD\u003c\/li\u003e\n\u003cli\u003eInfections in Cancer Patients – Lindsey Baden, MD\u003c\/li\u003e\n\u003cli\u003eSymptom Management in Patients with Cancer – Janet L. Abrahm, MD\u003c\/li\u003e\n\u003cli\u003eCommunication: The Key to Excellence in End-of-Life Care – Susan D. Block, MD\u003c\/li\u003e\n\u003cli\u003eBiology of Hematopoietic Stem Cell Transplantation – Robert J. Soiffer, MD\u003c\/li\u003e\n\u003cli\u003eBiology of Acute Leukemia and Myelodysplastic Syndromes – Benjamin L. Ebert, MD, PhD\u003c\/li\u003e\n\u003cli\u003eAcute Leukemias – Daniel J. DeAngelo, MD, PhD\u003c\/li\u003e\n\u003cli\u003eMyelodysplastic Syndrome – David P. Steensma, MD\u003c\/li\u003e\n\u003cli\u003eChronic Myelogenous Leukemia – Joseph H. Antin, MD\u003c\/li\u003e\n\u003cli\u003eMyeloproliferative Syndromes – Ann M. Mullally, MD\u003c\/li\u003e\n\u003cli\u003eMultiple Myeloma – Kenneth C. Anderson, MD\u003c\/li\u003e\n\u003cli\u003eWaldenstrom Macroglobulinemia, Amyloidosis – Irene M. Ghobrial, MD\u003c\/li\u003e\n\u003cli\u003eLow Grade Lymphomas – Caron A. Jacobson, MD\u003c\/li\u003e\n\u003cli\u003eHigh Grade Lymphomas – Eric D. Jacobsen, MD\u003c\/li\u003e\n\u003cli\u003eHodgkin’s Lymphoma – Ann S. LaCasce, MD\u003c\/li\u003e\n\u003cli\u003eDiagnosis and Treatment of CLL and Related B Cell Malignancies – Matthew S. Davids, MD\u003c\/li\u003e\n\u003cli\u003eHead and Neck Cancer – Robert I. Haddad, MD\u003c\/li\u003e\n\u003cli\u003eNatural History, Screening, Surgery, Small Cell Lung Cancer – Bruce E. Johnson, MD\u003c\/li\u003e\n\u003cli\u003eNon Small Cell Lung Cancer – Mark Awad, MD, PhD\u003c\/li\u003e\n\u003cli\u003eMesothelioma and Thymoma – David M. Jackman, MD\u003c\/li\u003e\n\u003cli\u003eThyroid Cancer – Jochen Lorch, MD\u003c\/li\u003e\n\u003cli\u003eCarcinoid and Pancreatic Neuroendocrine Tumors – Jennifer Ang Chan, MD\u003c\/li\u003e\n\u003cli\u003eEsophageal and Gastric Cancer – Peter C. Enzinger, MD\u003c\/li\u003e\n\u003cli\u003ePancreatic and Hepatobiliary Cancer – Brian M. Wolpin, MD\u003c\/li\u003e\n\u003cli\u003eAnal Cancers – Robert J. Mayer, MD\u003c\/li\u003e\n\u003cli\u003eColorectal Cancers – Robert J. Mayer, MD\u003c\/li\u003e\n\u003cli\u003eGastrointestinal Cancer – Genetic Syndromes – Matthew Yurgelun, MD\u003c\/li\u003e\n\u003cli\u003eGerm Cell Tumor – Maximizing Cure While Minimizing the Burden of Therapy – Mark M. Pomerantz, MD\u003c\/li\u003e\n\u003cli\u003eRenal and Bladder Cancer – Toni K. Choueiri, MD\u003c\/li\u003e\n\u003cli\u003eProstate Cancer Part I: Overview and Management of Localized Disease – Atish Choudhury, MD, PhD\u003c\/li\u003e\n\u003cli\u003eProstate Cancer Part II: Management of Disseminated Prostate Cancer – Atish Choudhury, MD, PhD\u003c\/li\u003e\n\u003cli\u003eMelanoma – F. Stephen Hodi, MD\u003c\/li\u003e\n\u003cli\u003eSarcomas and Gastrointestinal Stromal Tumors (GIST) – George D. Demetri, MD\u003c\/li\u003e\n\u003cli\u003eOvarian Cancer – Ursula A. Matulonis, MD\u003c\/li\u003e\n\u003cli\u003eCervical and Endometrial Cancer – Panagiotis A. Konstantinopoulos, MD, PhD\u003c\/li\u003e\n\u003cli\u003eNeuro-oncology – David A. Reardon, MD\u003c\/li\u003e\n\u003cli\u003eBreast Cancer: Risk Factors, Genetics, Screening and Prevention – Judy E. Garber, MD, MPH\u003c\/li\u003e\n\u003cli\u003eBreast Cancer: Advances in Staging, Prognosis, Surgery and Radiation, and DCIS – Harold J. Burstein, MD, PhD\u003c\/li\u003e\n\u003cli\u003eManagement for HER2-Positive and Triple Negative Breast Cancer – Eric P. Winer, MD\u003c\/li\u003e\n\u003cli\u003eBreast Cancer Survivorship – Ann H. Partridge, MD, MPH\u003c\/li\u003e\n\u003cli\u003eHematopoiesis and Cytokines – David T. Scadden, MD\u003c\/li\u003e\n\u003cli\u003eAcquired Bone Marrow Failure – Julie-Aurore Losman, MD, PhD\u003c\/li\u003e\n\u003cli\u003eCongenital Bone Marrow Failure – David A. Williams, MD\u003c\/li\u003e\n\u003cli\u003eHemophagocytic Syndromes and Related Immunodeficiencies – Barbara A. Degar, MD\u003c\/li\u003e\n\u003cli\u003eAnemia: An Overview – Ronald P. McCaffrey, MD\u003c\/li\u003e\n\u003cli\u003eIron Deficiency and Iron Overload – Mark D. Fleming, MD, PhD\u003c\/li\u003e\n\u003cli\u003eImmune Hemolytic Anemia – Richard M. Kaufman, MD\u003c\/li\u003e\n\u003cli\u003eNon-immune Hemolytic Anemia – David E. Golan, PhD, MD\u003c\/li\u003e\n\u003cli\u003eSickle Cell Disease – Maureen M. Achebe, MD, MPH\u003c\/li\u003e\n\u003cli\u003eThalassemia and Other Hemoglobinopathies – Matthew M. Heeney, MD\u003c\/li\u003e\n\u003cli\u003eDisorders of Neutrophils – Nancy Berliner, MD\u003c\/li\u003e\n\u003cli\u003eAcquired Thrombocytopenias – Elisabeth M. Battinelli, MD, PhD\u003c\/li\u003e\n\u003cli\u003eHemophilia – Aric D. Parnes, MD\u003c\/li\u003e\n\u003cli\u003eVon Willebrand Disease and Congenital Platelet Disorders – Nathan T. Connell, MD, MPH\u003c\/li\u003e\n\u003cli\u003eCongenital and Acquired Thrombophilia – Kenneth A. Bauer, MD\u003c\/li\u003e\n\u003cli\u003eNew Oral Anticoagulants – Jean M. Connors, MD\u003c\/li\u003e\n\u003cli\u003eTransfusion Medicine for the Clinician – Walter H. Dzik, MD\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eLearning Objectives\u003c\/h3\u003e\n\u003cdiv\u003eUpon completion of this activity, the participant will be able to:\u003c\/div\u003e\n\u003cul\u003e\n\u003cli\u003eApply current\/recommended Hematology and Oncology guidelines in clinical practice\u003c\/li\u003e\n\u003cli\u003ePerform differential diagnosis of complex clinical presentations related to Hematologic and Oncologic disorders\u003c\/li\u003e\n\u003cli\u003eIdentify\/apply current therapeutic options for for specific Hematologic and Oncologic disorders\u003c\/li\u003e\n\u003cli\u003eEvaluate and interpret up-to-date literature relevant to clinical practice in Hematology and Oncology\u003c\/li\u003e\n\u003cli\u003eIllustrate knowledge of pathophysiology as it applies to management of Hematology and Oncology disorders\u003c\/li\u003e\n\u003cli\u003eApply knowledge gained to the ABIM certification\/recertification Hematology and Oncology examinations\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eIntended Audience\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003eThe activity was planned for fellows\/trainees, practicing Hematology and Oncology specialists (MDs), and other professional affiliates (internists with an interest in Hematology and Oncology) who are preparing to take ABIM Board Review or Recertification Examinations, or who seek CME activities to improve patient care in the areas of Hematology and Oncology Medicine.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cdiv\u003eDate of Original Release: June 30, 2018\u003c\/div\u003e\n\u003cdiv\u003eTermination Date: June 30, 2021\u003c\/div\u003e\n\u003cdiv\u003e\u003c\/div\u003e","brand":"meducours","offers":[{"title":"Default Title","offer_id":42954308321378,"sku":"MED-AMB00907","price":15.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0662\/9549\/6802\/files\/0001866_the-brigham-and-dana-farber-board-review-in-hematology-and-oncology.jpg?v=1779370830","url":"https:\/\/meducourse.com\/products\/the-brigham-and-dana-farber","provider":"Meducourse","version":"1.0","type":"link"}